Copart extends tender offer for ACV Auctions to October 7

Copart extended its $10.50-per-share cash tender offer for ACV Auctions to October 7, 2026, after withdrawing and refiling its Hart-Scott-Rodino notification to give U.S. antitrust regulators more time to review the deal. About 81.27 million ACV shares, or 47.78% of shares outstanding, had been tendered as of Tuesday, below the more-than-50% minimum condition. The HSR waiting period is scheduled to expire October 13 unless terminated earlier, leaving completion contingent on regulatory clearance and additional shareholder tenders.

Analysis

ACVA is now a classic closing-arbitrage instrument rather than a fundamental AI/auto-market auction exposure. With only 47.8% tendered against a >50% condition, the critical variable over the next week is incremental holder participation; the modest shortfall is generally solvable, but the refiling introduces a discrete regulatory-duration risk that can keep the spread wider than a routine tender offer. A successful close should anchor ACVA near $10.50, while a DOJ/FTC second request or adverse action would reprice it on standalone value and likely produce a sharp gap down.

For CPRT, the direct acquisition cost is unlikely to be the valuation driver; the more relevant issue is whether regulators view combining salvage-auction scale with ACVA's dealer/wholesale marketplace as a data, channel-access, or auction-fee concentration concern. Even if approved, integration creates a longer-term competitive question for KAR's OPENLANE (KAR): a combined CPRT/ACVA could cross-sell vehicle disposition, inspection, logistics, and digital-auction services, raising customer-acquisition costs and pressuring take rates across wholesale auto auctions over 6-18 months.

The market may be overpricing a binary antitrust outcome relative to the near-term evidence: refiling often reflects review timing rather than a substantive objection. The key falsifier is not the October 13 statutory date alone, but any second-request disclosure, extension beyond ordinary HSR timing, or tender participation failing to clear 50% as expiry approaches. Absent those signals, the annualized return on ACVA's remaining cash spread may be attractive, but position sizing must reflect substantial break risk rather than treating it as Treasury-like carry.

Key Decisions for Investors

• Event-driven: buy ACVA only if the gross spread to $10.50 remains sufficiently wide to compensate for binary break risk; use the October 7 tender deadline and October 13 HSR expiry as decision points. Avoid adding after a second request or material HSR extension, which would materially worsen expected duration and closing probability.
• Monitor ACVA tender participation daily where available; a move above the 50% minimum before expiry materially de-risks the transaction, while participation remaining below roughly 49% into the final 24-48 hours warrants reducing exposure regardless of headline optimism.
• Maintain CPRT as a watch rather than a directional M&A trade: downside in a blocked deal is limited by its standalone business, but upside from closing is likely too small versus company-specific operating and valuation risks. Reassess if management quantifies acquisition synergies or regulators impose conduct remedies that weaken the strategic rationale.
• For a 6-18 month competitive expression after regulatory clearance, investigate a relative short KAR versus CPRT only after confirming overlap in dealer-auction customer cohorts and pricing. Falsify the thesis if KAR retains or expands take rates and dealer volumes through the first two post-close reporting periods.